24
2025-07
Suzhou, 24 July, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety.
25
2025-06
Receipt Of JNCI Designation For KT-939
Suzhou, 25 June, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed KT-939 has passed the review of the Japanese Nomenclature Cosmetic Ingredient (the “JNCI”) by the Japanese Cosmetic Industry Committee. The officially assigned name is メチルオキセタンカルバミドチアゾリルレゾルシノ一ル. Such designation approval signifies that KT-939 may commence application and sales as a cosmetic raw material in Japan market, laying a material foundation for the Company’s expansion in the functional cosmetic raw material market, helping further promote the demand for products of the Company and driving the company to become a leading supplier of the functional cosmetic raw material.
23
2025-05
In the newly announced entry list of the Inspiration Hive zone at the 2025 New York Society of Cosmetic Chemists (NYSCC) exhibition, Kintor’s innovative ingredient KT-939 has been selected as the only "Chinese ingredient" among the numerous global ones. It will compete with global industry giants such as Ashland, DSM-Firmenich, and Eastman, marking a groundbreaking milestone that China’s cosmetic ingredient R&D stands at the forefront of global innovation.
08
2025-05
Suzhou, 8 May, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the global sales business of its self-developed KT-939, a functional raw material for whitening and freckle-removing cosmetics, has officially commenced. The Company has recently completed its first sales of this raw material. This signifies that the Company has officially tapped into the functional cosmetic raw material industry with an aim to provide high-quality and safe cosmetic raw material for the global cosmetic market.
02
2025-05
Suzhou, 2 May, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that a clinical observational study of KX-826 in combination with minoxidil for the treatment of male adults with AGA in China has reached the primary endpoint.
20
2025-03
Suzhou, 20 March, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the long-term safety phase III clinical trial of its in-house developed and potential first-in-class KX-826 tincture for the treatment of AGA has obtained top-line results. Results indicated that the Long-term Safety Clinical Trial has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent safety and efficacy.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn